Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH)‘s stock had its “hold” rating reaffirmed by Jefferies Group LLC in a research note issued on Friday. They presently have a $1.75 price target on the biopharmaceutical company’s stock, down from their previous price target of $2.25. Jefferies Group LLC’s price objective indicates a potential upside of 37.80% from the company’s current price.

Several other research firms have also recently issued reports on ANTH. Zacks Investment Research upgraded Anthera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, June 13th. ValuEngine cut Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $10.11.

Shares of Anthera Pharmaceuticals (NASDAQ:ANTH) traded down 5.93% during mid-day trading on Friday, reaching $1.27. The company’s stock had a trading volume of 431,980 shares. Anthera Pharmaceuticals has a 1-year low of $0.30 and a 1-year high of $3.55. The company’s 50 day moving average price is $1.52 and its 200-day moving average price is $1.13. The company’s market capitalization is $8.03 million.

Anthera Pharmaceuticals (NASDAQ:ANTH) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.09) by $1.12. Analysts predict that Anthera Pharmaceuticals will post ($3.88) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/jefferies-group-llc-reaffirms-hold-rating-for-anthera-pharmaceuticals-inc-anth/1474421.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. raised its position in Anthera Pharmaceuticals by 1,376.1% in the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 335,595 shares during the period. Sabby Management LLC raised its stake in shares of Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock worth $748,000 after buying an additional 1,665,655 shares during the last quarter. Finally, UBS Group AG raised its stake in shares of Anthera Pharmaceuticals by 9.9% in the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 33,901 shares during the last quarter.

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Analyst Recommendations for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.